针对癌症治疗的免疫调节检查点的新型抗体。
Novel antibodies targeting immune regulatory checkpoints for cancer therapy.
机构信息
Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK.
出版信息
Br J Clin Pharmacol. 2013 Aug;76(2):233-47. doi: 10.1111/bcp.12164.
Abstract
Cancers must evade or suppress the immune system in order to develop. Better understanding of the molecular regulation governing tumour detection and effective activation of the immune system (so called immune regulatory checkpoints) has provided new targets for cancer immunotherapy. Therapeutic monoclonal antibodies against these targets are currently undergoing clinical evaluation with more in pre-clinical development; buoyed by the recent licence approval of the anti-CTLA-4 antibody, ipilumumab, for use in melanoma. This article will review the current status of the various antibodies and target molecules being investigated.
摘要
癌症必须逃避或抑制免疫系统才能发展。更好地了解控制肿瘤检测和有效激活免疫系统（所谓的免疫调节检查点）的分子调控为癌症免疫治疗提供了新的靶点。针对这些靶点的治疗性单克隆抗体目前正在进行临床评估，更多的则处于临床前开发阶段；最近 CTLA-4 抗体伊匹单抗(ipilumumab)被批准用于黑色素瘤，这一进展令人鼓舞。本文将综述正在研究的各种抗体和靶分子的现状。
相似文献
1
Novel antibodies targeting immune regulatory checkpoints for cancer therapy.针对癌症治疗的免疫调节检查点的新型抗体。
Br J Clin Pharmacol. 2013 Aug;76(2):233-47. doi: 10.1111/bcp.12164.
2
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.检查点阻断癌症免疫疗法靶向肿瘤特异性突变抗原。
Nature. 2014 Nov 27;515(7528):577-81. doi: 10.1038/nature13988.
3
The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies.实体恶性肿瘤免疫检查点抑制的现状
Surg Oncol Clin N Am. 2019 Jul;28(3):369-386. doi: 10.1016/j.soc.2019.02.008.
4
Therapeutic Antibodies in Cancer Therapy.癌症治疗中的治疗性抗体。
Adv Exp Med Biol. 2016;917:95-120. doi: 10.1007/978-3-319-32805-8_6.
5
Current status of immunotherapy.免疫疗法的现状。
Jpn J Clin Oncol. 2016 Mar;46(3):191-203. doi: 10.1093/jjco/hyv201. Epub 2016 Jan 26.
6
Human tumour-associated antigens: targets for monoclonal antibody-mediated cancer therapy.人类肿瘤相关抗原：单克隆抗体介导的癌症治疗靶点
Cancer Surv. 1985;4(1):271-90.
7
Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.针对免疫检查点受体和分子的自然杀伤细胞治疗调节。
Front Immunol. 2018 Sep 10;9:2041. doi: 10.3389/fimmu.2018.02041. eCollection 2018.
8
Checkpoint blockade immunotherapy for cancer comes of age.癌症的检查点阻断免疫疗法已走向成熟。
J Natl Cancer Inst. 2015 Mar 5;107(3). doi: 10.1093/jnci/djv069. Print 2015 Mar.
9
Monoclonal antibodies for cancer immunotherapy.用于癌症免疫治疗的单克隆抗体。
Lancet. 2009 Mar 21;373(9668):1033-40. doi: 10.1016/S0140-6736(09)60251-8.
10
Editorial: Is the Recent Burst of Therapeutic Anti-tumor Antibodies the Tip of an Iceberg?社论：近期治疗性抗肿瘤抗体的爆发是冰山一角吗？
Front Immunol. 2018 Mar 5;9:442. doi: 10.3389/fimmu.2018.00442. eCollection 2018.
引用本文的文献
1
Nanomechanical binding mechanism of ligands drives agonistic activity.配体的纳米机械结合机制驱动激动活性。
Nat Commun. 2025 Jul 19;16(1):6674. doi: 10.1038/s41467-025-61929-1.
2
10 years of BiTE immunotherapy: an overview with a focus on pancreatic cancer.双特异性T细胞衔接器（BiTE）免疫疗法十年综述：聚焦胰腺癌
Front Oncol. 2024 Dec 20;14:1429330. doi: 10.3389/fonc.2024.1429330. eCollection 2024.
3
Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy.纳米抗体作为创新的免疫检查点调节剂：推动癌症免疫治疗
Med Oncol. 2024 Dec 24;42(1):36. doi: 10.1007/s12032-024-02588-y.
4
Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments.免疫调节性单克隆抗体作为研究肿瘤细胞上PD-1/PD-L1顺式相互作用以及建立安全有效的联合治疗早期筛选方法的工具。
Cancers (Basel). 2021 Jun 8;13(12):2858. doi: 10.3390/cancers13122858.
5
MicroRNA-326 attenuates immune escape and prevents metastasis in lung adenocarcinoma by targeting PD-L1 and B7-H3.微小RNA-326通过靶向程序性死亡配体1（PD-L1）和B7-H3减轻肺腺癌的免疫逃逸并预防转移。
Cell Death Discov. 2021 Jun 15;7(1):145. doi: 10.1038/s41420-021-00527-8.
6
Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells.分离出两种对肿瘤细胞和自然杀伤细胞具有有趣生物学特性的新型人抗CTLA-4单克隆抗体。
Cancers (Basel). 2020 Aug 6;12(8):2204. doi: 10.3390/cancers12082204.
7
Novel Human Bispecific Aptamer-Antibody Conjugates for Efficient Cancer Cell Killing.用于高效杀伤癌细胞的新型人双特异性适体-抗体偶联物
Cancers (Basel). 2019 Aug 29;11(9):1268. doi: 10.3390/cancers11091268.
8
The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition.免疫检查点抑制背景下的甲状腺癌免疫全景。
Int J Mol Sci. 2019 Aug 13;20(16):3934. doi: 10.3390/ijms20163934.
9
Impact of Human FcγR Gene Polymorphisms on IgG-Triggered Cytokine Release: Critical Importance of Cell Assay Format.FcγR 基因多态性对 IgG 触发的细胞因子释放的影响：细胞检测方法的重要性。
Front Immunol. 2019 Mar 7;10:390. doi: 10.3389/fimmu.2019.00390. eCollection 2019.
10
Soluble immune checkpoints in cancer: production, function and biological significance.可溶性免疫检查点在癌症中的作用：产生、功能和生物学意义。
J Immunother Cancer. 2018 Nov 27;6(1):132. doi: 10.1186/s40425-018-0449-0.
本文引用的文献
1
Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release.TGN1412 试验灾难细胞因子风暴的严重程度与白介素-2 的释放相关。
Br J Clin Pharmacol. 2013 Aug;76(2):299-315. doi: 10.1111/bcp.12165.
2
PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.PD-1 表达的肿瘤浸润 T 细胞是 HPV 相关头颈部癌症的有利预后生物标志物。
Cancer Res. 2013 Jan 1;73(1):128-38. doi: 10.1158/0008-5472.CAN-12-2606. Epub 2012 Nov 7.
3
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.伊匹单抗联合紫杉醇和卡铂作为广泛期小细胞肺癌的一线治疗：一项随机、双盲、多中心 2 期临床试验的结果。
Ann Oncol. 2013 Jan;24(1):75-83. doi: 10.1093/annonc/mds213. Epub 2012 Aug 2.
4
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.抗 PD-L1 抗体在晚期癌症患者中的安全性和活性。
N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.
5
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.抗 PD-1 抗体在癌症中的安全性、活性和免疫相关性。
N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.
6
Management of immune-related adverse events and kinetics of response with ipilimumab.伊匹单抗治疗免疫相关不良反应的管理和反应动力学。
J Clin Oncol. 2012 Jul 20;30(21):2691-7. doi: 10.1200/JCO.2012.41.6750. Epub 2012 May 21.
7
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.伊匹单抗联合紫杉醇和卡铂作为 IIIB/IV 期非小细胞肺癌一线治疗：一项随机、双盲、多中心 II 期研究的结果。
J Clin Oncol. 2012 Jun 10;30(17):2046-54. doi: 10.1200/JCO.2011.38.4032. Epub 2012 Apr 30.
8
Properties of mouse and human IgG receptors and their contribution to disease models.鼠和人 IgG 受体的特性及其在疾病模型中的作用。
Blood. 2012 Jun 14;119(24):5640-9. doi: 10.1182/blood-2012-01-380121. Epub 2012 Apr 25.
9
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.抗 CD40 人源化单克隆抗体 lucatumumab（HCD122）治疗复发慢性淋巴细胞白血病的 I 期研究。
Leuk Lymphoma. 2012 Nov;53(11):2136-42. doi: 10.3109/10428194.2012.681655. Epub 2012 Jun 12.
10
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.一项评估 Brentuximab vedotin 治疗复发或难治性霍奇金淋巴瘤患者的关键性 II 期研究结果。
J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26.
Zotero 插件